MannKind Corporation focuses on the discovery, development, and commercialization of therapeutic products for patients with diseases such as diabetes. The Company's lead product candidate, Afrezza, is in late-stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. Afrezza is a rapid-acting inhaled insulin therapy indicated to improve glycemic control in adults with diabetes. Taken at the start of a meal using a specially designed inhaler, Afrezza dissolves rapidly upon inhalation to the deep lung and delivers insulin quickly to the bloodstream.

Type
Public
HQ
Westlake Village, US
Founded
1991
Size (employees)
250 (est)+64%
MannKind Corporation was founded in 1991 and is headquartered in Westlake Village, US
Report incorrect company information

Key People/Management at MannKind Corporation

Michael Castagna

Michael Castagna

Chief Executive Officer
Steven Binder

Steven Binder

Chief Financial Officer
Joseph Kocinsky

Joseph Kocinsky

Chief Technology Officer
David Kendall

David Kendall

Chief Medical Officer
Courtney Barton

Courtney Barton

VP, Chief Compliance and Privacy Officer
Stuart Tross

Stuart Tross

Chief People Officer
Show more

MannKind Corporation Office Locations

MannKind Corporation has offices in Danbury and Westlake Village
Westlake Village, US (HQ)
301 30930 Russell Ranch Rd
Show all (2)
Report incorrect company information

MannKind Corporation Financials and Metrics

MannKind Corporation Financials

MannKind Corporation's revenue was reported to be $11.75 m in FY, 2017 which is a 93.3% decrease from the previous period.
USD

Revenue (Q1, 2018)

3.5 m

Gross profit (Q1, 2018)

(543 k)

Gross profit margin (Q1, 2018), %

(15.7%)

Net income (Q1, 2018)

(30.4 m)

EBIT (Q1, 2018)

(26.8 m)

Market capitalization (21-May-2018)

267.4 m

Closing share price (21-May-2018)

1.9

Cash (31-Mar-2018)

26.7 m
MannKind Corporation's current market capitalization is $267.4 m.
Annual
USDFY, 2015FY, 2016FY, 2017

Revenue

174.8 m11.7 m

Revenue growth, %

(100%)(93%)

Cost of goods sold

67.4 m17.1 m17.2 m

Gross profit

157.6 m(5.5 m)
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Revenue

162.4 m3 m2.2 m2 m3.5 m

Cost of goods sold

1.9 m5.7 m8.1 m7.5 m3.7 m4.3 m2.5 m11.9 m8.3 m4 m

Gross profit

(1.9 m)(5.7 m)(8.1 m)(7.5 m)(3.7 m)158 m461 k(9.8 m)(6.2 m)(543 k)

Gross profit Margin, %

97%15%(452%)(304%)(16%)
Annual
USDFY, 2015FY, 2016FY, 2017

Cash

59.1 m22.9 m43.9 m

Accounts Receivable

30.9 m2.8 m

Prepaid Expenses

4 m4.4 m3 m

Inventories

2.3 m2.7 m
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Cash

120.8 m107.2 m32.9 m27.7 m63.7 m35.5 m48 m43.4 m20.1 m26.7 m

Accounts Receivable

4.3 m4.7 m1.7 m144 k3.1 m438 k1.3 m1.8 m1.6 m

Prepaid Expenses

16.4 m14.1 m2.8 m1.4 m4.5 m3.5 m2.6 m3.1 m

Inventories

16.8 m19.8 m23.4 m2.9 m5.1 m3.7 m3.2 m3.1 m3.9 m
Annual
USDFY, 2015FY, 2016FY, 2017

Net Income

(368.4 m)125.7 m(117.3 m)

Depreciation and Amortization

13.3 m4.2 m3.5 m

Inventories

13.5 m(2.3 m)(3.3 m)

Accounts Payable

8.4 m(12.1 m)3.8 m
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Net Income

(30.7 m)(59.6 m)(91.4 m)(24.9 m)(54.8 m)71.7 m(16.3 m)(51.7 m)(84.5 m)(30.4 m)

Depreciation and Amortization

3 m6.6 m10.1 m1 m2.1 m3.1 m908 k1.8 m2.7 m706 k

Inventories

26.4 m(10.1 m)(13.7 m)(2.9 m)(5.1 m)(1.4 m)(841 k)(798 k)(1.8 m)

Accounts Payable

3.3 m(2.2 m)(2.7 m)(14.8 m)(12.5 m)(10.3 m)(1.7 m)3.4 m2.1 m(2 m)
USDY, 2018

Financial Leverage

-0.3 x
Show all financial metrics

MannKind Corporation Operating Metrics

MannKind Corporation's Patent Applications was reported to be 200 in FY, 2017.
FY, 2014FY, 2015FY, 2016FY, 2017

Patents Issued

292 330 425 530

Patent Applications

230 350 250 200
Show all operating metrics
Report incorrect company information

MannKind Corporation News and Updates

Report incorrect company information